177 related articles for article (PubMed ID: 14871989)
1. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
[TBL] [Abstract][Full Text] [Related]
2. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
3. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
4. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
5. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
10. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma.
Triozzi PL; Aldrich W; Allen KO; Lima J; Shaw DR; Strong TV
Int J Cancer; 2005 Jan; 113(3):406-14. PubMed ID: 15455351
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Kudo-Saito C; Garnett CT; Wansley EK; Schlom J; Hodge JW
Cancer Immunol Immunother; 2007 Dec; 56(12):1897-910. PubMed ID: 17503041
[TBL] [Abstract][Full Text] [Related]
16. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
[TBL] [Abstract][Full Text] [Related]
17. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
19. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]